Showing 2341-2350 of 4063 results for "".
- Avellino Hits 1-Million Genetic Test Milestonehttps://modernod.com/news/avellino-hits-1-million-genetic-test-milestone/2478164/Avellino announced that the company has performed over 1-million genetic and molecular diagnostic tests. This milestone includes over 821,000 universal tests for TGFBI corneal dystrophy, over 180,000 AvellinoSARS-CoV-2/COVID-19 (AvellinoCoV2) tests since March 2020, and the November 2019 launch o
- Johnson & Johnson Forges $1-Billion Pact to Supply US with COVID-19 Vaccinehttps://modernod.com/news/johnson-johnson-forges-1-billion-pact-to-supply-us-with-covid-19-vaccine/2478133/Johnson & Johnson said it entered into an agreement with the US government for the large-scale domestic manufacturing and delivery of 100 million doses of its investigational SARS-CoV-2 vaccine Ad26.COV2.S for use in the country. Specifically, the US Biomedical Advanced Research and Developme
- Novavax Reports Positive Early Results for Experimental COVID-19 Vaccine NVX-CoV2373https://modernod.com/news/novavax-reports-positive-early-results-for-experimental-covid-19-vaccine-nvx-cov2373/2478122/Novavax announced preliminary data from a phase 1/2 study indicating that its recombinant coronavirus vaccine candidate NVX-CoV2373 triggered immune responses in healthy adults and was generally well-tolerated. According to findings in a paper, Novavax submitted to the preprint server medRxiv, th
- MeiraGTx Announces Positive Clinical Data of Investigational Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/meiragtx-announces-positive-clinical-data-of-investigational-gene-therapy-for-x-linked-retinitis-pigmentosa/2478062/MeiraGTx Holdings announced 6-month data from the ongoing phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa (XLRP) with genetically confirmed variants in the RPGR gene. Significant improve
- Tracking Aerosols During Eye Surgerieshttps://modernod.com/news/tracking-aerosols-during-eye-surgeries/2478046/There is growing evidence that the novel coronavirus, SARS-CoV-2, could spread through aerosols—tiny droplets that can remain suspended in the air for hours in closed spaces. Aerosols generated during surgeries and outpatient procedures can be risky to healthcare workers, according to a Medical X
- Interim 6-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosahttps://modernod.com/news/interim-6-month-data-of-rpgr-gene-therapy-shows-significant-vision-improvement-in-patients-living-with-x-linked-retinitis-pigmentosa/2478036/The Janssen Pharmaceutical Companies of Johnson & Johnson announced 6-month data from the ongoing phase 1/2 trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of
- Moderna’s COVID-19 Vaccine Candidate Induces “Robust” Response In All Patients Testedhttps://modernod.com/news/modernas-covid-19-vaccine-candidate-induces-robust-response-in-all-patients-tested/2478023/The NEJM published an interim analysis Tuesday of an ongoing phase 1 trial showing that Moderna’s experimental COVID-19 vaccine mRNA-1273 induced anti–SARS-CoV-2 immune responses in all participants, with the authors saying there were “no trial-limiting safety concerns.”
- Laboratory Studies Confirm Betadine Antiseptic Products’ Effectiveness Against COVID-19 Virushttps://modernod.com/news/laboratory-studies-confirm-betadine-antiseptic-products-effectiveness-against-covid-19-virus/2477989/Mundipharma announced that laboratory testing at the Duke-NUS Medical School in Singapore has confirmed the effectiveness of its Betadine antiseptic products against the novel coronavirus (SARS-CoV-2). Testing has demonstrated Betadine strong in-vitro virucidal activity, killing 99.99% of
- Plex Pharmaceuticals Awarded $1.6 Million in Grant Funding from NIH to Advance Eye Drop Therapy for Cataractshttps://modernod.com/news/plex-pharmaceuticals-awarded-1-6-million-in-grant-funding-from-nih-to-advance-eye-drop-therapy-for-cataracts/2477987/Plex Pharmaceuticals announced that it has been awarded two Small Business Innovation Research grants from the National Institutes of Health (NIH) National Eye Institute: a $1.3 million phase 2 grant (R44EY027236) and a $300,000 phase 1
- Apellis Completes Enrollment in Two Phase 3 Studies of Pegcetacoplan in Patients with Geographic Atrophy (GA)https://modernod.com/news/apellis-completes-enrollment-in-two-phase-3-studies-of-pegcetacoplan-in-patients-with-geographic-atrophy-ga/2477978/Apellis Pharmaceuticals announced that it completed enrollment in the phase 3 DERBY and OAKS studies investigating intravitreal pegcetacoplan (APL-2), a targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GA causes blind